Focus: Lantern Pharma is a Dallas-based public company focused on AI-driven personalized cancer therapy, leveraging computational drug development to advance oncology treatments. The company operates as a mid-cap biotech with a lean R&D model and a diversified pipeline across multiple cancer indications.
Profile data last refreshed 16h ago · AI intelligence enriched 1w ago
No open roles listed right now. Follow Lantern Pharma to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Lantern Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Lantern Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Lantern Pharma at ThinkEquity Conference: AI drug push gains pace - Investing.com
Lantern Pharma at ThinkEquity Conference: AI drug push gains pace Investing.com
Lantern Pharma to Present at ThinkEquity Conference, Highlighting AI-Driven Cancer Drug Development - citybuzz -
Lantern Pharma to Present at ThinkEquity Conference, Highlighting AI-Driven Cancer Drug Development citybuzz -
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 15th, 2026 - Business Wire
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 15th, 2026 Business Wire
Lantern Pharma Inc. (LTRN) stock price, news, quote and history - Yahoo Finance Australia
Lantern Pharma Inc. (LTRN) stock price, news, quote and history Yahoo Finance Australia
Lantern Pharma hosts webinar on Open‑Medicine AI multi-agentic drug development platform - TradingView
Lantern Pharma hosts webinar on Open‑Medicine AI multi-agentic drug development platform TradingView
Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET - Business Wire
Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET Business Wire
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Phase 1a Evaluation of LP-184 in Recurrent Glioblastoma: Safety, Pharmacokinetics, and Translational Optimization of CNS Exposure.
Quantitative characterization of platelet count and alanine aminotransferase dynamics to inform personalized dosing in the first-in-human LP-184 trial.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo